Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating trilaciclib in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cosela (trilaciclib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 3 | Status: COMPLETED